Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
23 Abril 2024 - 9:30AM
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”
or the “Company”), a biopharmaceutical company focused on
developing and advancing novel therapeutics for patients living
with autoimmune, inflammatory, and fibrotic diseases, today
announced it has entered into a transformative strategic
collaboration with Strand Life Sciences, a leading bioinformatics
specialist, aimed at advancing precision medicine for ulcerative
colitis (UC) therapy.
The collaboration with Strand Life Sciences
provides Palisade Bio access to advanced bioinformatics tools vital
for understanding complex disease pathways and predicting responses
to PDE4 inhibitors. Leveraging data from over ten UC clinical
studies, Palisade has curated a pipeline of 1600 UC patient
samples, including transcriptomics and clinical outcomes. This
curated dataset, analyzed using in-house tools, enables Palisade to
identify biomarkers for selecting UC patient responders, utilizing
machine learning to develop a precision medicine approach to
patient selection.
"Our partnership with Strand Life Sciences
signifies a pivotal advancement in our mission to revolutionize UC
treatment," said Dr. Mitch Jones, CMO at Palisade Bio. "By
harnessing the power of bioinformatics and leveraging extensive
patient datasets, we are highly optimistic in our ability to
deliver personalized therapies that offer new hope to patients
living with UC. More immediately, the findings from this
collaboration will provide valuable guidance and insight for our
lead program, PALI-2108."
"We are thrilled to collaborate with Palisade
Bio in this transformative endeavor toward advancing precision
medicine for ulcerative colitis therapy," added Ramesh Hariharan,
CEO at Strand Life Sciences. "Our expertise in bioinformatics,
machine learning/AI and knowledge curation towards biomarker
stratification, combined with Palisade's extensive patient
datasets, holds immense promise in identifying predictive
biomarkers and ultimately improving outcomes for UC patients."
Palisade Bio is committed to advancing precision
medicine solutions for UC and other inflammatory indications. The
Company is advancing its collaborative efforts with Strand Life
Sciences and other partners to continue driving innovation and
transforming the landscape of UC treatment.
About Palisade
Bio Palisade Bio is a biopharmaceutical company
focused on developing and advancing novel therapeutics for patients
living with autoimmune, inflammatory, and fibrotic diseases. The
Company believes that by using a targeted approach with its novel
therapeutics it will transform the treatment landscape. For more
information, please go to www.palisadebio.com.
About Strand Life Sciences
Strand Life Sciences is a multiomics research and diagnostics
company that combines a long track record in bioinformatics with
cutting-edge, laboratory assays and a vast hospital partner network
that enables omics-based biomarker discovery. Strand’s customers
include global instrument, diagnostic and pharmaceutical companies.
For more information, please go to us.strandls.com.
Forward Looking Statements
This communication contains “forward-looking”
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements regarding the Company’s intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the extent of our cash runway; our
ability to successfully develop our licensed technologies;
estimates about the size and growth potential of the markets for
our product candidates, and our ability to serve those markets,
including any potential revenue generated; future regulatory,
judicial, and legislative changes or developments in the United
States (U.S.) and foreign countries and the impact of these
changes; our ability to maintain the Nasdaq listing of our
securities; our ability to build a commercial infrastructure in the
U.S. and other markets; our ability to compete effectively in a
competitive industry; our ability to identify and qualify
manufacturers to provide API and manufacture drug product; our
ability to enter into commercial supply agreements; the success of
competing technologies that are or may become available; our
ability to attract and retain key scientific or management
personnel; the accuracy of our estimates regarding expenses, future
revenues, capital requirements and needs for additional financing;
our ability to obtain funding for our operations; our ability to
attract collaborators and strategic partnerships; and the impact of
the COVID-19 pandemic or any global event on our business, and
operations, and supply. Any statements contained in this
communication that are not statements of historical fact may be
deemed to be forward-looking statements. These forward-looking
statements are based upon the Company’s current expectations.
Forward-looking statements involve risks and uncertainties. The
Company’s actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, the Company’s ability to advance its
nonclinical and clinical programs, the uncertain and time-consuming
regulatory approval process; and the Company’s ability to secure
additional financing to fund future operations and development of
its product candidates. Additional risks and uncertainties can be
found in the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2023, filed with the Securities and
Exchange Commission (“SEC”) on March 26, 2024. These
forward-looking statements speak only as of the date hereof and the
Company expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company’s
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are
based.
Investor Relations ContactJTC
Team, LLCJenene Thomas 833-475-8247PALI@jtcir.com
Palisade Bio (NASDAQ:PALI)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Palisade Bio (NASDAQ:PALI)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024